Odronextamab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase II program in Diffuse Large B-Cell Lymphoma. According to Globaldata, it is involved in 12 clinical trials, of which 5 are ongoing, and 7 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Odronextamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Odronextamab is expected to reach an annual total of $229 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Odronextamab is under development for the treatment of relapsed/refractory B- cell non-Hodgkin's lymphomas including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, B-cell Hodgkin's lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia. The therapeutic candidate is administered intravenously. It is an anti-CD20 and anti-CD3 bi-specific monoclonal antibody. It is developed based on VelociSuite technology.
Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
The company reported revenues of (US Dollars) US$12,172.9 million for the fiscal year ended December 2022 (FY2022), a decrease of 24.3% over FY2021. The operating profit of the company was US$4,738.9 million in FY2022, compared to an operating profit of US$8,946.8 million in FY2021. The net profit of the company was US$4,338.4 million in FY2022, compared to a net profit of US$8,075.3 million in FY2021.
For a complete picture of Odronextamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.